Clinical safety and efficacy of the first-in-class Rho kinase inhibitor for lowering IOP: netarsudil and the fixed-dose combination of netarsudil and latanoprost €15.00 Clinical safety and efficacy of the first-in-class Rho kinase inhibitor for lowering IOP: netarsudil and the fixed-dose combination of netarsudil and latanoprost quantity Add to cart Category: Articles Tag: Volume 3 Description Description Authors: Janet B. Serle, Jake Radell Related products The interleukin-20 (IL-20) story €15.00 Add to cart Laser alteration of the collector channels ostia. Pivotal paradigm shift from laser photocoagulation to laser photostimulation €15.00 Add to cart The role of blood flow in glaucoma €15.00 Add to cart Glaucoma and stem cells €15.00 Add to cart